Deutsche Bank raised the firm’s price target on Sandoz to CHF 33 from CHF 28 and keeps a Hold rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
- Sandoz Canada announces launch of Jubbonti, Wyost
- Sandoz receives FDA approval for Enzeevu
- Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
- Sandoz reports second-quarter sales and half-year 2024 results
Questions or Comments about the article? Write to editor@tipranks.com